ValuEngine upgraded shares of Theratechnologies (OTCMKTS:THERF) from a hold rating to a buy rating in a research note published on Thursday, ValuEngine reports.
Shares of OTCMKTS:THERF opened at $4.09 on Thursday. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.69 and a quick ratio of 2.19. Theratechnologies has a 52-week low of $3.85 and a 52-week high of $8.85. The firm has a 50 day moving average price of $4.86.
Theratechnologies (OTCMKTS:THERF) last issued its quarterly earnings data on Thursday, July 11th. The company reported ($0.04) earnings per share (EPS) for the quarter. Theratechnologies had a negative net margin of 8.78% and a negative return on equity of 4.97%. The firm had revenue of $15.61 million during the quarter.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Read More: What is the Fibonacci sequence?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.